Antengene (HKSE:06996) Other Long-Term Liabilities : HK$89.78 Mil (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Antengene Other Long-Term Liabilities?

Antengene's other long-term liabilities for the quarter that ended in Jun. 2024 was HK$89.78 Mil.

Antengene's quarterly other long-term liabilities increased from Jun. 2023 (HK$0.00 Mil) to Dec. 2023 (HK$94.68 Mil) but then declined from Dec. 2023 (HK$94.68 Mil) to Jun. 2024 (HK$89.78 Mil).

Antengene's annual other long-term liabilities increased from Dec. 2021 (HK$-0.00 Mil) to Dec. 2022 (HK$0.00 Mil) and increased from Dec. 2022 (HK$0.00 Mil) to Dec. 2023 (HK$94.68 Mil).

Antengene Other Long-Term Liabilities Historical Data

The historical data trend for Antengene's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antengene Other Long-Term Liabilities Chart

Antengene Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long-Term Liabilities

Get a 7-Day Free Trial

Antengene Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Other Long-Term Liabilities	Get a 7-Day Free Trial							-	-	-	-	-

Antengene Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Antengene Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Antengene's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Antengene Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antengene Corp Ltd (HKSE:06996) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

1065 West Zhongshan Road, Suites 1206-1209, Block B, Zhongshan SOHO Plaza, Changning District, Shanghai, CHN

Website

https://www.antengene.com

Antengene Corp Ltd is a clinical-stage biopharmaceutical company focused on oncology medicines. The company produces drugs such as selinexor, eltanexor, verdinexor, and other products. It also engages in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics for the treatment of hematologic malignancies and solid tumors. Geographically it operates in Chinese Mainland, Hong Kong, Macao and Taiwan and Overseas.

Executives

Jay Mei 2023 Grat	2201 Interest of corporation controlled by you
Mei Jay	2201 Interest of corporation controlled by you
Begonia Investment Ltd.	2101 Beneficial owner
Qiming Corporate Gp V, Ltd.
The Core Trust Company Limited	2301 Trustee
Tct (bvi) Limited	2501 Other
Fountainvest China Capital Partners Gp3 Ltd.	2201 Interest of corporation controlled by you
Fountainvest China Capital Partners Fund Iii, L.p.	2201 Interest of corporation controlled by you
Fmr Llc	2201 Interest of corporation controlled by you
Fidelity Investment Trust	2101 Beneficial owner
Jay Mei 2020 Grat	2201 Interest of corporation controlled by you
Meiland Pharma Tech Spc
Boyu Capital Group Holdings Ltd	2201 Interest of corporation controlled by you
Boyu Capital General Partner Iii, Ltd
Boyu Capital General Partner Iii, L.p.

Antengene Headlines

No Headlines